Company profile
Rubicon Organics Inc.
OTC: ROMJF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#455 of 1,418 Healthcare companies by revenue65th-percentile growth
EA Score
63CFH 65DQ —GM 60SS 55
v0.1 · 45/100 weight · provisional
↑ return on assets, return on equity · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$46.5M
Rev growth YoY (TTM)
+17.7%
Net income (FY)
$751.2k
Employees
266
as of 2026-08-21
Market cap
$26.7M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$42.5M59.4M CAD2025
Net income$751.2k1.1M CAD2025
Operating income-$11.0M-15.3M CAD2025
Total assets$48.8M66.8M CAD2025
Liabilities$16.6M22.8M CAD2025
Equity$32.1M44.0M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rubicon Organics Inc.’s revenue?
Rubicon Organics Inc. booked $42.5M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a 1.8% net margin.
Peers · Healthcare
Xilio Therapeutics, Inc.38DMedAvail Holdings, Inc.——Wave Life Sciences Ltd.63CSS Innovations International, Inc.53DCoherus Oncology, Inc.61CBiofrontera Inc.46DKey facts
CEOMargaret Ruth Brodie
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: ROMJF
Employees266
IPO date2018-10-24
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.